Skip to main content

Table 1 Baseline patient characteristics of patients with AITL receiving first allo-HCT reported to the CIBMTR from 2000 to 2016

From: Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis

Variable

N = 249 (%)

Median age at HCT, years (range)

56 (21–77)

Male gender

150 (60)

Race

 Caucasian

214 (86)

 African American

5 (2)

 Othersa

17 (7)

 Missing

13 (5)

Karnofsky performance score ≥ 90

119 (48)

 < 90

113 (45)

 Missing

17 (7)

HCT-CI

 0

46 (18)

 1–2

53 (21)

 ≥ 3

84 (34)

 Not available before 2007

55 (22)

 Missing

11 (4)

Interval from diagnosis to HCT, months

 Median (range)

14 (3–118)

Median lines of therapy before HCT (range)

3 (1–5)

Remission status at HCT

 Complete remission

108 (43)

 Partial remission

90 (36)

 Chemorefractory

38 (15)

 Untreated/unknown

13 (5)

History of prior autologous HCT

98 (39)

TBI in conditioning

83 (34)

ATG/alemtuzumab in conditioningb

59 (24)

Conditioning intensityc

 Myeloablative conditioning

66 (27)

 Non-myeloablative/RIC

183 (73)

Graft source

 Bone marrow

8 (3)

 Peripheral blood

241 (97)

Donor type

 HLA-identical sibling

140 (56)

 Unrelated donor 8/8

109 (44)

Donor/recipient CMV status

 Both negative

72 (29)

 Both positive

59 (24)

 Either donor/recipient +

69 (28)

 Missing

49 (19)

Graft-versus-host disease prophylaxis

 Calcineurin inhibitor + MTX ± othersd (except MMF)

119 (48)

 Calcineurin inhibitor + MMF ± othersd

76 (31)

 Calcineurin inhibitor + others (except MMF)

40 (16)

 Othersd

10 (4)

 Missing

4 (2)

Year of HCT

 2000–2006

47 (19)

 2007–2011

82 (33)

 2012–2016

120 (48)

Median follow-up of survivors (range), months

49 (4–170)

  1. ATG antithymocyte globulin, CMV cytomegalovirus, HCT hematopoietic cell transplantation, HCT-CI HCT-Comorbidity index, MMF mycophenolate mofetil, MTX methotrexate, TBI total body irradiation, RIC reduced intensity conditioning
  2. aOthers: 13 Asian; 3 Hispanic or Latino; 1 race unspecified, non-Hispanic
  3. bATG/alemtuzumab—49 ATG alone; 10 alemtuzumab alone
  4. cFor details, refer to Additional file 1: Table S4
  5. dFor details, refer to Additional file 1: Table S5